Drug Approval | July 24, 2025
Zydus receives tentative approval from USFDA for Ibrutinib tablets
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Subscribe To Our Newsletter & Stay Updated
